LivaNova PLC (LIVN) - Cash Flow Conversion Efficiency

Latest as of March 2026: 0.013x

Based on the latest financial reports, LivaNova PLC (LIVN) has a cash flow conversion efficiency ratio of 0.013x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($15.22 Million) by net assets ($1.21 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Review LIVN FCF to total liabilities ratio to assess the company's free cash flow relative to its total liabilities.

LivaNova PLC - Cash Flow Conversion Efficiency Trend (1992–2025)

This chart illustrates how LivaNova PLC's cash flow conversion efficiency has evolved over time, based on yearly financial data. Also see how much is LivaNova PLC worth for the company's overall valuation and market capitalisation.

LivaNova PLC Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of LivaNova PLC ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
flatexDEGIRO AG
XETRA:FTK
1.644x
Jiangsu Pacific Quartz Co Ltd
SHG:603688
-0.008x
Catalyst Pharmaceuticals Inc
NASDAQ:CPRX
0.059x
BBVA Banco Frances SA
BA:BBAR
0.203x
Indorama Ventures PCL
BK:IVL
0.120x
Guangzhou Haige Communications Group Incorporated Co
SHE:002465
-0.018x
Shenzhen Jove Enterprise Co. Ltd.
SHE:300814
0.051x
AMP Ltd
AU:AMP
-0.316x

Annual Cash Flow Conversion Efficiency for LivaNova PLC (1992–2025)

The table below shows the annual cash flow conversion efficiency of LivaNova PLC from 1992 to 2025. View LivaNova PLC stock price for real-time trading data and today's change.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-12-31 $1.20 Billion $254.30 Million 0.212x +52.86%
2024-12-31 $1.32 Billion $183.04 Million 0.139x +136.44%
2023-12-31 $1.28 Billion $74.91 Million 0.059x +1.30%
2022-12-31 $1.21 Billion $69.90 Million 0.058x -26.92%
2021-12-31 $1.29 Billion $102.54 Million 0.079x +210.66%
2020-12-31 $1.11 Billion $-79.40 Million -0.072x -8.67%
2019-12-31 $1.38 Billion $-91.14 Million -0.066x -182.20%
2018-12-31 $1.50 Billion $120.50 Million 0.080x +59.33%
2017-12-31 $1.82 Billion $91.30 Million 0.050x -4.82%
2016-12-31 $1.71 Billion $90.20 Million 0.053x +20.14%
2015-12-31 $1.81 Billion $79.68 Million 0.044x -78.97%
2014-12-31 $259.10 Million $54.20 Million 0.209x 0.00%
2013-12-31 $259.10 Million $54.20 Million 0.209x -39.26%
2012-12-31 $229.57 Million $79.05 Million 0.344x -15.79%
2011-12-31 $183.47 Million $75.03 Million 0.409x +43.86%
2010-12-31 $175.45 Million $49.87 Million 0.284x +14.84%
2009-12-31 $173.27 Million $42.89 Million 0.248x -0.61%
2008-12-31 $98.74 Million $24.59 Million 0.249x -73.03%
2007-12-31 $15.65 Million $14.46 Million 0.923x -33.88%
2006-12-31 $-14.81 Million $-20.69 Million 1.397x +109.12%
2005-12-31 $4.63 Million $-70.88 Million -15.308x -29052.47%
2004-12-31 $75.60 Million $-3.97 Million -0.053x -200.75%
2003-12-31 $68.98 Million $3.60 Million 0.052x +175.46%
2002-12-31 $67.42 Million $1.28 Million 0.019x +103.55%
2001-12-31 $43.02 Million $-22.95 Million -0.533x -77.18%
1999-12-31 $27.15 Million $-8.18 Million -0.301x +31.59%
1998-12-31 $33.40 Million $-14.70 Million -0.440x -9.73%
1997-12-31 $36.90 Million $-14.80 Million -0.401x -63.11%
1996-12-31 $48.80 Million $-12.00 Million -0.246x +96.16%
1995-12-31 $1.50 Million $-9.60 Million -6.400x -600.95%
1994-12-31 $6.90 Million $-6.30 Million -0.913x -201.63%
1993-12-31 $18.50 Million $-5.60 Million -0.303x -51.98%
1992-12-31 $24.10 Million $-4.80 Million -0.199x --

About LivaNova PLC

NASDAQ:LIVN USA Medical Devices
Market Cap
$4.32 Billion
Market Cap Rank
#4219 Global
#1453 in USA
Share Price
$78.58
Change (1 day)
+2.75%
52-Week Range
$49.57 - $85.33
All Time High
$130.95
About

LivaNova PLC, a medical technology company, designs, develops, manufactures, markets, and sells products, therapies, and services in the United States, the United Kingdom, Germany, France, Italy, the Netherlands, Spain, Belgium, Poland, Sweden, Switzerland, Austria, Norway, Portugal, Finland, Denmark, and internationally. The company operates in two segments, Cardiopulmonary and Neuromodulation. … Read more